Regulatory Requirements for Registration of Generic Drug Products in Japan
Abstract
Drug registration is a procedure of expertise of the pharmaceutical product quality, efficacy and safety by regulatory authority. The emergence of various formats has enabled the manufacturers of drugs to easily gain access into various markets and thus, was able to place their products in the market. The choice of Japan as one of the destinations for the market of the Drug products ensures the manufacturer a good market value. Japan is considered as one of the strongest and promised markets for the registration of the drugs. Of late, generic drugs are holding major stake in the pharmaceutical market and are gaining more and more confidence in the usage. Majority of medicines in Japan are generic drugs which are considered as value for the money and affordable. Generic drugs are pharmaceutical products that are approved for manufacture, and are prescribed as drugs with equivalent therapeutic effects to those of the original drugs. The quality, safety and efficacy of the generic drugs do not differ from those of the original drugs. In Japan, the expiry of drug patents has given rise to many generic products. The reduction in price provides its availability for the public in a cheaper price. Pharmaceuticals and Medical Devices Agency (PMDA) carries out the registration process of drug products in Japan. The registration process mainly includes specification, accelerated stability studies and bioequivalence rather than complete tests required for an innovator drug.
Keywords: PMDA, MHLW, generics, CTD, bioequivalence
Cite this Article
Daniel Sudi, Dixit Mudit. Regulatory requirements for registration of generic drug products in Japan. Trends in Drug Delivery. 2015; 2(2): 19–27p.
Downloads
Published
Issue
Section
License
Copyright Transfer and Declaration Form (Please compile this form, sign and send by e-mail and post)
Journal Title:
Title of the Paper:
Corresponding Author’s Information: Name: Address:
E-mail:
Contact Number: I
t is herein agreed that: The copyright to the above-listed unpublished and original article is transferred to STM Journals. This copyright transfer covers the exclusive right to reproduce and distribute the contribution, including reprints, translations, photographic reproductions, microform, electronic form (offline, online), or any other reproductions of similar nature. I/We declare that above manuscript is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere. I/ We warrant(s) that his/her/their contribution is original, except for such excerpts from copyrighted works as may be included with the permission of the copyright holder and author thereof, that it contains no libelous statements, and does not infringe on any copyright, trademark, patent, statutory right, or propriety right of others. I/We will not publish his/her/their above said contribution anywhere else without the prior written permission of the publisher unless it has been changed substantially.I/We also agree to the authorship of the article in the following order:Author(s) Name Signature(s)1. ________________2. ________________3. ________________4. ________________The author(s) agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal (comments if any to the editor can be added below).
